|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, we conclude that loss of E-cadherin and cytoplasmatic beta-catenin induces p38-mediated NFkappaB activation, potentially revealing an important mechanism of tumorigenesis in malignant melanomas.
|
15378016 |
2004 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We systematically examined melanoma cell lines for activating CTNNB1 mutations as well as genetic and epigenetic alterations of the adenomatous polyposis coli gene (APC), another key component of the Wnt signalling transduction pathway.
|
15133491 |
2004 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin.
|
15024079 |
2004 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the tumor suppressor gene melanoma differentiation-associated gene-7 (mda-7) induces apoptosis in many cancer cells, and adenoviral-mediated overexpression of mda-7 downregulates beta-catenin and PI 3-kinase signaling in breast cancer cells.
|
15300212 |
2004 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Genetic and epigenetic alterations of the APC gene in malignant melanoma.
|
15133491 |
2004 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
Mutational analysis of CTNNB1 identified somatic mutations in 1 primary melanoma and 1 melanoma metastasis from 2 different patients (5%).
|
12124804 |
2002 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A significant fraction of primary human melanomas exhibit deregulation (via aberrant nuclear accumulation) of beta-catenin, leading us to examine its role in melanoma growth and survival.
|
12235125 |
2002 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To determine whether this difference in mutation frequency reflected an in vitro culturing artefact, exon 3 of CTNNB1 was screened in a panel of 62 melanoma cell lines.
|
11930117 |
2002 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The results indicate that induction of Nr-CAM transcription by beta-catenin or plakoglobin plays a role in melanoma and colon cancer tumorigenesis, probably by promoting cell growth and motility.
|
12183361 |
2002 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Mutational analysis of CTNNB1 identified somatic mutations in 1 primary melanoma and 1 melanoma metastasis from 2 different patients (5%).
|
12124804 |
2002 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
One out of 62 (1.6%) cell lines was found to carry a mutation, indicating that aberration of the Wnt-1/wingless pathway through activation of beta-catenin is a rare event, even in melanoma cell lines.
|
11930117 |
2002 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry revealed a significant loss of membranous beta-catenin staining between the primary and metastatic melanomas as well as between radial and vertical growth phase.
|
11950921 |
2002 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
|
11950921 |
2002 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
One out of 62 (1.6%) cell lines was found to carry a mutation, indicating that aberration of the Wnt-1/wingless pathway through activation of beta-catenin is a rare event, even in melanoma cell lines.
|
11930117 |
2002 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Moreover, suppression of melanoma clonogenic growth by disruption of beta-catenin-T-cell transcription factor/LEF is rescued by constitutive MITF.
|
12235125 |
2002 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis of CTNNB1 identified somatic mutations in 1 primary melanoma and 1 melanoma metastasis from 2 different patients (5%).
|
12124804 |
2002 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.
|
11351304 |
2001 |
|
melanoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Beta-catenin is tyrosine phosphorylated in three melanoma cell lines and associates with both the ErbB2 receptor tyrosine kinase and the LAR receptor tyrosine phosphatase.
|
11245482 |
2001 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, beta-catenin exon 3 mutations are rare in primary as well as metastatic melanomas and do not explain the abnormal cytoplasmic and nuclear localization of beta-catenin found in a relatively large fraction of primary melanomas.
|
11351304 |
2001 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, it has been recently reported that beta-catenin mutations are rare in primary malignant melanoma, but its nuclear and/or cytoplasmic localization, a potential indicator of Wnt/beta-catenin pathway activation, is frequently observed in melanoma (Rimm et al., Am.J.Pathol., 154, 325-329, 1999).
|
11594745 |
2001 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
beta-catenin mutations have been found not only in melanoma and prostatic carcinoma but also in hepatocellular carcinomas in human, c-myc, H-ras genes transgenic mice and chemically-induced models.
|
10811985 |
2000 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A proportion of APC wild-type colon carcinomas and melanomas also contains constitutive nuclear Tcf-4/beta-catenin complexes as a result of dominant mutations in the N terminus of beta-catenin that render it insensitive to downregulation by APC, GSK3 beta, and Axin/Conductin.
|
10549354 |
2000 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings demonstrate that beta-catenin mutations are rare in primary melanoma, in contrast to the situation in melanoma cell lines.
|
10027390 |
1999 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.
|
10027390 |
1999 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutant forms of beta-catenin have been discovered in colon cancers that retain wild-type APC genes, and also in melanomas, medulloblastomas, prostate cancer and gastric and hepatocellular carcinomas.
|
10201372 |
1999 |